AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is increased by the enhanced FDA indication, which permits the system to be used for PE therapy. By lowering the thrombus burden and enhancing right ventricular function, the indication broadens the range of therapy alternatives available to PE patients. Price Performance In the past six months, ANGO's shares have lost 10.5% against the industry's rise of 20.6%. The S&P 500 has gained 19.8% in the same time frame. Image Source: Zacks Investment Research More on AlphaVac F1885 System The AlphaVac F1885 System is currently approved for use as an emergent first-line device for treating PE and removing thromboemboli from the venous system. The system consists of an obturator, a waste bag assembly, an ergonomic handle, and an 18F cannula angled at an angle of 85 degrees. To offer safety and efficacy information for a clearing unique to PE, the APEX-AV Study
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- Insider Spends US$67k Buying More Shares In AngioDynamics [Yahoo! Finance]Yahoo! Finance
- A Leaner AngioDynamics Is A High-Risk Execution-Driven Story [Seeking Alpha]Seeking Alpha
- AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates [Yahoo! Finance]Yahoo! Finance
- AngioDynamics upgraded at Oppenheimer on pipeline progress [Seeking Alpha]Seeking Alpha
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- 4/4/24 - Form 8-K
- ANGO's page on the SEC website